The role of LncRNA LBX2-AS1 in cancers: functions, mechanisms and potential clinical utility

被引:8
作者
Su, Yuanshuai [1 ]
Li, Chengzhi [2 ]
Fang, Yu [1 ]
Gu, Xinyu [1 ]
Zheng, Qiuxian [1 ]
Lu, Juan [1 ]
Li, Lanjuan [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1,Natl Med Ctr Infect Dis, Natl Clin Res Ctr Infect Dis,State Key Lab Diag &, Sch Med,Collaborat Innovat Ctr Diag & Treatment I, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China
关键词
Long noncoding RNA; LBX2-AS1; Oncogenic; Molecular mechanism; Cancer therapy; LONG NONCODING RNA; PRECISION ONCOLOGY; CELL-PROLIFERATION; PROSTATE-CANCER; GASTRIC-CANCER; METASTASIS; GLIOMA; EPIDEMIOLOGY; TECHNOLOGIES; EXPRESSION;
D O I
10.1007/s12094-022-02944-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increasingly advanced biology technique has revealed that long non-coding RNAs (lncRNA) as critical factors that exert significant regulatory effects on biological functions by modulating gene transcription, epigenetic modifications and protein translation. A newly emerging lncRNA, ladybird homeobox 2 (LBX2)-antisense RNA 1 (LBX2-AS1), was found to be highly expressed in various tumors. Moreover, it is functionally linked to the regulation of essential tumor-related biological processes, such as cell proliferation and apoptosis, through interactions with multiple signaling molecules/pathways. The important roles played by LBX2-AS1 in cancer initiation and progression suggest that this lncRNA has enormous clinical potential for use as a novel biomarker or therapeutic target. In this article, we retrospectively review the latest advances in research exploring the roles of the lncRNA LBX2-AS1 in oncology field, highlighting its involvement in a comprehensive network of molecular mechanisms underlying diverse cancers and examining its potential applications in clinical practice.
引用
收藏
页码:293 / 305
页数:13
相关论文
共 50 条
  • [31] Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance
    Hou, Junhui
    Zhang, Gong
    Wang, Xia
    Wang, Yuan
    Wang, Kefeng
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [32] Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance
    Junhui Hou
    Gong Zhang
    Xia Wang
    Yuan Wang
    Kefeng Wang
    Biomarker Research, 11
  • [33] MicroRNA Functions and Potential Clinical Utility in Glioblastoma
    Lawler, Sean E.
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2013, 8 (01) : 36 - 44
  • [34] RETRACTED ARTICLE: Long non-coding RNA LBX2-AS1 enhances glioma proliferation through downregulating microRNA-491-5p
    Qunbang Chen
    Jian Gao
    Yingjia Zhao
    Ruizhe Hou
    Cancer Cell International, 20
  • [35] Pathogenic mechanisms and the potential clinical value of circFoxo3 in cancers
    Zhang, Lei
    Wang, Yin
    Zhang, Yuan
    Zhao, Yanfang
    Li, Peifeng
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 23 : 908 - 917
  • [36] SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis
    Li, Wentao
    Soufiany, Ismatullah
    Lyu, Xiao
    Lu, Chenfei
    Wei, Yutian
    Shi, Zhumei
    You, Yongping
    JOURNAL OF CANCER, 2021, 12 (23): : 6989 - 7002
  • [37] ELK1-mediated upregulation of lncRNA LBX2-AS1 facilitates cell proliferation and invasion via regulating miR-491-5p/S100A11 axis in colorectal cancer
    Ma, Gang
    Dai, Weijie
    Zhang, Juan
    Li, Qianjun
    Gu, Biao
    Song, Yaqi
    Yang, Xiaozhong
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2021, 48 (01)
  • [38] Deciphering the oncogenic landscape: Unveiling the molecular machinery and clinical significance of LncRNA TMPO-AS1 in human cancers
    Saraswat, Shelesh Krishna
    Mahmood, Bashar Shaker
    Ajila, Freddy
    Kareem, Doaa Saadi
    Alwan, Mariem
    Athab, Zainab H.
    Shaier, Jalal Brism
    Hosseinifard, Seyed Reza
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 255
  • [39] LncRNA SBF2-AS1: A Budding Star in Various Cancers
    Tan, Fangshun
    Chen, Jinlan
    Wang, Bei
    Du, Zhuoying
    Mou, Jie
    Wu, Yinxin
    Liu, Yuling
    Zhao, Fangnan
    Yuan, Chengfu
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (18) : 1513 - 1522
  • [40] Biological functions and potential mechanisms of miR-143-3p in cancers (Review)
    Wu, Jia
    Zhu, Ying
    Liu, Dandan
    Cong, Qingwei
    Bai, Changchuan
    ONCOLOGY REPORTS, 2024, 52 (03)